Radar · Life Sciences in Rockville
Best Life Sciences Companies in Rockville, United States
The 117 best Life Sciences companies in Rockville, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sucampo.
By Riya SenguptaFinancials
117companies tracked
$2.4Bdisclosed funding
0unicorns
69have raised
Ranked: Best Life Sciences companies in Rockville
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Sucampo Pharmaceutical company focused on specialty generics and innovative therapies | $300M | 114 mo ago | 139 | — | — | 69 patents Prostaglandin analog drugs for gastrointestinal, inflammatory, and neuropathic pain therapies | — |
| 2 | Arcellx Developer of T cell-mediated anti tumour therapy | $200M | 40 mo ago | 130 130 → 224 (+72%) · sector median +12% | David Hilbert Founder & Co-CEO | WordPressApple iCloud MailMySQL+19 | 112 patents Engineered D-domain polypeptides for multifunctional immune cell therapy applications | — |
| 3 | Sanaria Developer of whole-parasite malaria vaccines for infectious diseases 48Funding top 23%Patents top 33%Moat top 41%Innovation top 46% All 8 signals ▾Fundingtop 23% Patentstop 33% Moattop 41% Innovationtop 46% Growthtop 47% Marketbottom 44% Techbottom 44% Globalbottom 37% Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $188M | 9 mo ago | 77 | — | WordPressMySQLPHP+21 | 134 patents Malaria vaccine production, sporozoite cryopreservation, and vector storage technologies | — |
| 4 | Clasp Therapeutics Developer of T cell therapeutics for the treatment of cancer | $150M | 27 mo ago | — | Shibin Zhou Co-Founder | — | — | 1 award |
| 5 | MacroGenics Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | 87 mo ago | 339 339 → 378 (+12%) · sector median +12% | Scott Koenig President and CEO | — | 1,258 patents Therapeutic antibodies and ADCs targeting immune checkpoints (PD‑1, CD3, ADAM9, B7‑H3). | — |
| 6 | Regenxbio Developer of AAV Gene Therapy for rare genetic diseases | $108M | 69 mo ago | 344 344 → 389 (+13%) · sector median +12% | — | DrupalPHPAmazon Web Services+17 | 490 patents AAV vector manufacturing and glycosylated enzyme gene‑therapy delivery | 1 award |
| 7 | HighTide Therapeutics Developer of small molecule based therapeutics for the treatment of liver, gastrointestinal, and metabolic… | $107M | 41 mo ago | 68 | — | — | — | 1 launch |
| 8 | Immunomic Therapeutics Vaccines for allergy, cancer and infectious disease. 57Funding top 24%Growth top 28%Product top 30%Innovation top 34% All 9 signals ▾Fundingtop 24% Growthtop 28% Producttop 30% Innovationtop 34% Moattop 39% Techbottom 44% Marketbottom 37% Globalbottom 37% Newsbottom 21% Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $98M | 12 mo ago | 51 | — | WordPressMySQLPHP+28 | — | — |
| 9 | TissueGene Developer of regenerative therapies for orthopedic diseases | $95M | 24 mo ago | 58 58 → 80 (+38%) · sector median +12% | Moon Noh CEO | BootstrapApache HTTP ServerjQuery+7 | 83 patents Regenerative cell/gene therapies for nerve, disc repair and immune‑mediated inflammation | 8 job openings |
| 10 | OpGen Developer of diagnostics and bioinformatics platforms for providers | $78M | 63 mo ago | 100 | — | WordPressMySQLPHP+16 | 111 patents Antimicrobial resistance profiling and rapid antibiotic susceptibility testing technologies. | — |
| 11 | OncoImmune Therapeutics for autoimmune disease (such as GVHD) and cancer (AML). | $74M | 69 mo ago | 6 | Ming You Co-Founder | — | 151 patents Immune checkpoint antibodies and CD24-based biologics for cancer, infectious and neuro diseases | — |
| 12 | Promaxo Developer of portable MRI for the cancer diagnostics market | $72M | 3 mo ago | 22 22 → 55 (+150%) · sector median +12% | Irving Weinberg Co-Founder | WordPressMySQLPHP+32 | 212 patents Patents concentrated in computing, sensing & instrumentation | — |
| 13 | OriGene Provider and manufacturer of proteins, antibodies, and other molecular tools for research applications | $70M | 132 mo ago | 141 141 → 130 (-8%) · sector median +12% | — | Cart FunctionalityMagentoMySQL+34 | 9 patents Protein microarray platforms for biomarker discovery, disease diagnostics, and gene expression profiling | 1 launch |
| 14 | CASI Pharmaceuticals Developer of therapeutics for the treatment of cancer 60Product top 19%Funding top 26%Growth top 36%Innovation top 38% All 10 signals ▾Producttop 19% Fundingtop 26% Growthtop 36% Innovationtop 38% Fin. healthtop 43% Markettop 46% Moatbottom 49% Globalbottom 44% Newsbottom 41% Techbottom 33% Product: 3 distinct product lines · Company stage: Public Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $69M | 5 mo ago | 234 | — | DudaNginxSnowplow Analytics+12 | — | — |
| 15 | American Gene Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases 55Funding top 24%Patents top 31%Moat top 35%Talent top 35% All 11 signals ▾Fundingtop 24% Patentstop 31% Moattop 35% Talenttop 35% Innovationtop 37% Growthtop 40% Producttop 40% Techtop 46% Marketbottom 36% Globalbottom 36% Newsbottom 22% Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $53M | 7 mo ago | 31 | Jeff Galvin Chief Executive Officer | WordPressMySQLPHP+34 | 228 patents Non-integrating viral vectors for gene delivery and HIV immunotherapy, plus gamma‑delta T‑cell activation | — |
| 16 | OncoC4 Developer of immunotherapy for cancer patients 62Patents top 17%Innovation top 21%Funding top 28%Moat top 33% All 7 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 28% Moattop 33% Globalbottom 43% Marketbottom 42% Newsbottom 34% Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $52M | 8 mo ago | 41 | — | — | 128 patents Immune checkpoint antibody therapeutics, especially anti‑CTLA‑4 combos for cancer treatment | 1 job opening |
| 17 | Maxim Biomedical Diagnostic testing solutions improving public health and healthcare worldwide | $50M | 29 mo ago | 22 22 → 15 (-32%) · sector median +12% | Joe Ma Founder & President | — | — | — |
| 18 | Abvacc Developer of vaccines and therapeutics to treat infectious diseases 35Funding top 30%Moat top 38%Patents top 43%Innovation top 50% All 7 signals ▾Fundingtop 30% Moattop 38% Patentstop 43% Innovationtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 31% Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $46M | 12 mo ago | — | M Aman Founder | — | 6 patents Vaccines targeting bacterial toxins and cell‑wall domains for immunotherapy | — |
| 19 | Tendyne Holdings Innovating structural heart solutions for improved patient outcomes and quality life | $37M | 145 mo ago | 40 | — | — | 281 patents Transcatheter heart valve prostheses and implantation anchoring systems | — |
| 20 | Synthetic Biologics Developing oncolytic virus therapies to overcome solid tumor barriers | $31M | 46 mo ago | 21 | — | — | 208 patents Microbiome-protective enzyme therapeutics and engineered biologics for infection and metabolic control | — |
| 21 | Trophogen Protein engineering for potent glycoprotein hormone and growth factor analogs | $31M | 94 mo ago | 6 | Bruce Weintraub President | — | 97 patents Manufacturing long-acting, highly glycosylated therapeutic glycoprotein hormones and analogs. | — |
| 22 | Supernus Pharmaceuticals Innovating CNS treatments, improving lives through neurological and psychiatric solutions | $30M | 143 mo ago | 652 652 → 845 (+30%) · sector median +12% | Jack Khattar President & CEO | DrupalPHPAmazon Web Services+24 | 403 patents Novel CNS therapeutic small molecules and modified-release formulations for neurological disorders | — |
| 23 | Cellphire Therapeutics Developer of platelet-derived therapeutics to address bleeding control and hemostasis challenges | $25M | 6 mo ago | 51 51 → 48 (-6%) · sector median +12% | Mike Gaffney CEO | — | — | — |
| 24 | ReveraGen Developer of steroids for treating Duchenne muscular dystrophy | $23M | 56 mo ago | — | Kanneboyina Nagaraju Co-Founder | — | — | — |
| 25 | Protein Potential Provides protein services | $23M | 118 mo ago | — | Kim Lee Sim Founder & President | — | 9 patents Oral live-attenuated bacterial vaccine platforms targeting shigellosis, typhoid, and COVID-19 | — |
| 26 | Therabron Biotech company developing a new class of drugs using secretoglobin proteins for management of respiratory… | $20M | 113 mo ago | 9 | — | — | — | — |
| 27 | Innovative Biosensors Developer of self-contained biosensor system for rapid diagnostic tests | $20M | 171 mo ago | 1 | — | — | — | — |
| 28 | Cytimmune Multifunctional and tumor-targeted cancer therapies | $15M | 65 mo ago | 1 | Lawrence Tamarkin Co-Founder | — | — | — |
| 29 | Sigmovir Developing the cotton rat as a model for human infectious disease research | $15M | 22 mo ago | 13 | Kevin Yim Co-founder | — | — | — |
| 30 | BioSET Biopharmaceutical company focused on reproductive medicine, gastroenterology, and urology | $12M | 181 mo ago | 9 | Tom Roueche ex-CEO & President | — | — | — |
| 31 | Benevir Innovative medicine, therapies, and medical technology for global healthcare solutions | $11M | 103 mo ago | 10 | — | — | — | — |
| 32 | Creative Bio-Peptides Developer of oral peptide treatments for neurodegenerative diseases | $11M | 12 mo ago | — | Michael Ruff Founder & CEO | — | — | — |
| 33 | Vigene Biosciences Developer of life science research reagents for drug discovery and functional genomics | $10M | 74 mo ago | 45 | Zairen Sun CEO | — | — | — |
| 34 | SYNAPS Dx Developer of a diagnostic test to detect Alzheimer's disease | $10M | 51 mo ago | 22 | Frank Amato CEO & President | WebflowGSAPSwiper+14 | 2 patents Secure attachment mechanisms for cochlear implant external transmitters | — |
| 35 | IBT Bio Services CRO providing preclinical and clinical research services, reagents, and animal models | $8M | 156 mo ago | 21 | — | — | — | — |
| 36 | CosmosID Developer of next-generation sequencing (NGS) technologies for the detection of microorganisms | $7M | 84 mo ago | 7 | — | WordPressMySQLPHP+23 | 19 patents Microbial DNA sequencing for identification, quantification, and trait analysis of microorganisms. | — |
| 37 | BioMarker Strategies Develops Cancer Diagnostics System | $7M | 104 mo ago | 8 | Jerry Parrott President | — | 31 patents Predictive biomarkers and assays for enhancing immune checkpoint inhibitor cancer therapy | — |
| 38 | Theranostics Health Personalized medicine through proteomic-based diagnostics and therapeutics for improved healthcare | $7M | 129 mo ago | 5 | Luis Gutierrez President & CEO | — | — | — |
| 39 | AMI Cardiac Monitoring Developer of cardiac health monitoring devices | $7M | 24 mo ago | 22 | Dot Glodek CEO | — | — | — |
| 40 | AAVogen Gene therapies to strengthen muscle and fight muscle wasting diseases | $6M | 34 mo ago | — | Buel Dan Rodgers Founder & CSO | — | 4 patents SMAD7 gene therapy vectors for treating muscle wasting and enhancing muscle mass | — |
| 41 | miRecule Developing microRNA therapies for the treatment of cancers | $5M | 9 mo ago | 8 | Anthony Saleh Co-Founder & CEO | WordPressMySQLPHP+14 | 52 patents Muscle‑targeted imaging agents and nucleic‑acid therapeutics for neuromuscular disorders | 1 award |
| 42 | Creatv Bio Developer of blood based tests for treating cancer | $4M | 81 mo ago | 9 | — | — | — | — |
| 43 | NeuroCytonix Developer of medical devices for the treatment of neurodegenerative diseases | $4M | 38 mo ago | 5 | — | Craft CMSApple iCloud MailMicrosoft 365+10 | — | — |
| 44 | Fina Biosolutions Conjugate vaccine solutions, bioconjugation services, and functionalized dextrans for emerging markets | $3M | 20 mo ago | 8 | — | — | 91 patents Efficient cytoplasmic production of soluble recombinant therapeutic proteins | — |
| 45 | Tethys Research Enzyme and metabolite discovery through unique methodologies for chemical product innovation | $3M | 58 mo ago | — | Robyn Kravit CEO | — | — | — |
| 46 | Silvec Developer of RNA-based genetic breeding solutions for plants | $2M | 12 mo ago | 26 26 → 13 (-50%) · sector median +12% | Anne Simon Co-Founder | — | — | — |
| 47 | Shuttle Pharma Developer of therapies to improve outcome of radiation therapy in cancer suffering patients | $1M | 12 mo ago | 7 | — | WordPressMySQLPHP+13 | — | — |
| 48 | Polaris Genomics Developer genomic-based diagnostics and therapeutics for neurological conditions | $800K | 10 mo ago | 10 | Tshaka Cunningham Co-Founder | — | — | — |
| 49 | Rise Therapeutics Developer of targeted immunological-based biologics for gastrointestinal (GI) inflammatory disease | $200K | 13 mo ago | 10 | Neil Fanger Co-Founder | — | — | — |
Top 12 Life Sciences companies in Rockville
#1
Series C · Rockville, Maryland · founded 2016 · 22 employees$72.3Mraised▾
Series C · Rockville, Maryland · founded 2016 · 22 employees
Developer of portable MRI for the cancer diagnostics market. Its platform technology enables collection and analysis of imaging data points for prostate imaging in a shorter time frame than conventional MRIs. First application is prostate cancer screening in patients with elevated PSA levels to determine the need of an invasive biopsy.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 4.3% of this cohort's audience
Funding rounds
- Mar 2026Series C$26.8M
- 2025Series C—
- Mar 2024Series C$41.9M
- Feb 2024Conventional Debt$550K
Founders & team
Investors
MicroPort Orthopedics, Kineticos, Huami, Zepp Labs, Medical Technology Venture Partners, Almond Tree Capital
Tech stack
Apache Http ServerAstraBluehostBootstrapCdnjsCloudflare
#2
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees$187.8Mraised▾
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees
Developer of whole-parasite malaria vaccines for infectious diseases. The company is developing protective vaccines against malaria and plasmodium falciparum infection in humans.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 23%Patents
top 33%Moat
top 41%Innovation
top 46%Growth
top 47%Market
bottom 44%Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 1/10 · IP moat: 134 patents
Funding rounds
- Sep 2025Grant (prize money)$2M
- Sep 2025Grant (prize money)$5.9M
- Jul 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$988.8K
Investors
NIAID, Gates, HHS
Tech stack
Animate.CssBootstrapContact Form 7Core-JsFont AwesomeGoogle Analytics
#3
Public · Rockville, Maryland · founded 1991 · 234 employees$69.5Mraised▾
Public · Rockville, Maryland · founded 1991 · 234 employees
Developer of therapeutics for the treatment of cancer. The company's pipeline includes ENMD-2076, a selective angiogenic kinase inhibitor, and 2ME2 for autoimmune disorders. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Product
top 19%Funding
top 26%Growth
top 36%Innovation
top 38%Fin. health
top 43%Market
top 46%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) · Last round Post IPO (Dec 2025)
Growth: Headcount 189 → 234 (+24%) across vintages · Revenue +99% YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Dec 2025Post IPO$5M
- Jun 2024Post IPO$15M
- Jan 2016Post IPO$10.3M
- Feb 2012Post IPO$10M
Investors
Accel, Emerging Technology Partners, IDG Capital, Aravis, Kleiner Perkins
Tech stack
AccessibeBluehostDudaHstsJqueryJquery Migrate
#4
Series B · Rockville, Maryland · founded 2008 · 31 employees$52.8Mraised▾
Series B · Rockville, Maryland · founded 2008 · 31 employees
Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases. The company has developed drugs using its delivery platform. The product pipeline includes a liver cancer therapeutic lentivirus and an AIDS therapeutic lentivirus, as well as Parkinson’s disease therapeutic lentivirus, and a familial dysautonomia therapeutic lentivirus.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 24%Patents
top 31%Moat
top 35%Talent
top 35%Innovation
top 37%Growth
top 40%Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) · Last round Series B (Nov 2025)
Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 228 patents · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series B$310K
- Apr 2022Series B$50M
- Nov 2015Series A$1.2M
- Sep 2015Grant (prize money)$232.2K
Founders & team
Investors
NIH, Ride wave ventures, HHS, Gaingels, Alumni Ventures
Tech stack
AddtoanyAddtoany Share ButtonsAmazon SesAmazon Web ServicesBeaver BuilderCdnjs
#5
Series A · Rockville, Maryland · founded 2005 · 51 employees$25.3Mraised▾
Series A · Rockville, Maryland · founded 2005 · 51 employees
Developer of platelet-derived therapeutics to address bleeding control and hemostasis challenges. The company develops stabilized cellular products like freeze-dried hemostatic agents and cryopreserved platelets targeting trauma, surgery, and military applications.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers · 37 engagements/post (5.5× cohort median)
Funding rounds
- Nov 2025Conventional Debt$3M
- Aug 2022Series A$5M
- Apr 2021Series A$15M
- Jun 2017Series A$3M
Founders & team
Investors
Simcah Management, Maryland Venture Fund, Military Health, Circadian Ventures
Tech stack
WebflowJqueryGoogle AnalyticsFont Awesome
#6
Series B · Rockville, Maryland · founded 2020 · 41 employees$52.3Mraised▾
Series B · Rockville, Maryland · founded 2020 · 41 employees
Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 17%Innovation
top 21%Funding
top 28%Moat
top 33%Global
bottom 43%Market
bottom 42%Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 · Latest publication 2026
Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21
Funding: Raised $52.3M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (Oct 2025)
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Research Associate
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series B$50M
- Apr 2020Grant (prize money)$2.3M
Investors
HHS, HM Capital, 3E Bioventures Capital, Kaitai Capital Management, GBA Fund, HM Venture Partners
#7
Series B · Rockville, Maryland · founded 2005 · 51 employees$97.9Mraised▾
Series B · Rockville, Maryland · founded 2005 · 51 employees
Immunomic Therapeutics develops lysosomal-associated membrane protein-based vaccines for the treatment of allergy and cancer. The company has partnered with Astellas to develop vaccines for Japnese red cedar (Phase 1), peanut allergy (Phase 1). Its immunology pipeline includes AST-VAC1 to treat acute myeloid leukemia (AML) (Phase 2); LAMP-Vax + pp64 DC therapy for brain cancer (Phase 1); ATTAC-II clinical trial (Phase II), etc.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 24%Growth
top 28%Product
top 30%Innovation
top 34%Moat
top 39%Tech
bottom 44%Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) · Last round Series B (May 2025)
Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo
Product: 8 distinct product lines · Company stage: Series B
Audience (LinkedIn): 4k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- May 2025Series B$6.5M
- Jan 2024Series B$3M
- Jan 2021Series B$77.7M
- Jul 2018Series A$314.5K
Investors
SBIR, Defense.gov, HLB, NIH, Keiretsu Forum, LSGPA
Tech stack
Animate.CssApache Http ServerBootstrapCloudflareCloudflare Browser InsightsContact Form 7
#8
Funding Raised · Rockville, Maryland · founded 2023$45.5Mraised▾
Funding Raised · Rockville, Maryland · founded 2023
Developer of vaccines and therapeutics to treat infectious diseases. The company's pipeline includes product candidates for the prevention and treatment of bacterial and viral infections. It has a bacterial program that primarily focuses on staphylococcal infections by targeting a variety of virulence factors such as toxins and critical enzymes produced by S. aureus. The company has also developed a large collection of potently neutralizing fully human and macaque-human chimeric antibody therapeutics and vaccines for filoviruses and the Nipah virus.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 30%Moat
top 38%Patents
top 43%Innovation
top 50%Talent
bottom 49%Market
bottom 37%Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) · Last round Grant (prize money) (May 2025)
Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents
Patents: 6 patents matched (strict assignee match) · 4 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Funding rounds
- May 2025Grant (prize money)$1.3M
- May 2025Grant (prize money)$1.3M
- Apr 2025Grant (prize money)$6.6M
- Feb 2025Grant (prize money)$3M
Founders & team
Investors
HHS
#9
Seed · Rockville, Maryland · founded 2018 · 8 employees$5.5Mraised▾
Seed · Rockville, Maryland · founded 2018 · 8 employees
Developing microRNA therapies for the treatment of cancers. The company's DREAmiR platform utilizes genomic data of patients to identify and develop disease-targeting therapeutics. The product pipeline includes MC-DX4 for Facioscapulohumeral Muscular Dystrophy (FSHD), and MC-30 for Head & Neck Squamous Cell Carcinoma (HNSCC)
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 partnerships · 1 awards (incl. Sanofi) announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$3.1M
- Apr 2025Grant (prize money)$3.1M
- Sep 2024Grant (prize money)$863.7K
- Sep 2021Grant (prize money)$1.9M
Founders & team
Investors
Maryland Momentum Fund, NIH SBIR/STTR, Alexandria, Boutique Venture Partners, Pathway Bioventures, FSHD Society
Tech stack
CloudflareCloudflare Browser InsightsContact Form 7DiviGoogle AnalyticsGoogle Font Api
#10
Funding Raised · Rockville, Maryland · founded 2017$10.9Mraised▾
Funding Raised · Rockville, Maryland · founded 2017
Developer of oral peptide treatments for neurodegenerative diseases. The company's proprietary platform is developing novel oral peptide immunotherapies for neurodegeneration, brain injuries, and chronic pain. It has developed chemokine receptor antagonist (CCR2/CCR5) peptides to block neuroinflammation and also delivers oral, brain penetrant small peptides that modulate innate immunity to reduce inflammation, lower cytokines, and neuroregeneration. The company is developing Dala1-peptide T-amide for Neuro-AIDS.
Funding rounds
- May 2025Grant (prize money)$2.5M
- Sep 2023Grant (prize money)$499.9K
- Sep 2021Grant (prize money)$4.9M
- Sep 2020Grant (prize money)$449.2K
Founders & team
Investors
HHS
#11
Series C · Rockville, Maryland · founded 1999 · 58 employees$94.6Mraised▾
Series C · Rockville, Maryland · founded 1999 · 58 employees
Developer of regenerative therapies for orthopedic diseases. Its lead product TG-C is an allogeneic cell therapy involving human chondrocytes engineered to produce the therapeutic protein TGF-1 to regenerate cartilage in patients with severe knee osteoarthritis (phase III). Its preclinical products in development are for bone, disc, and nerve regeneration.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 2.7% of this cohort's audience
Hiring: 9 hiring posts in 12 mo (public) · momentum +9 · hiring: Program Manager, Strategic Planning, Head of Medical Affairs
Funding rounds
- May 2024Series C$35M
- May 2023Series B$30M
- Aug 2022Series B$29.6M
- Jun 2017Grant (prize money)$750K
Founders & team
Investors
Maryland Stem Cell Research Fund, Q Capital Partners
Tech stack
Apache Http ServerBootstrapFancyboxGoogle AnalyticsGoogle Font ApiJquery
#12
Series A · Rockville, Maryland · founded 2020$150Mraised▾
Series A · Rockville, Maryland · founded 2020
Developer of T cell therapeutics for the treatment of cancer. The company is developing next-generation T cell engagers that target tumor-specific oncogenic driver mutations across hard-to-treat cancers.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers — 3.6% of this cohort's audience
Activity: 1 awards announced in 12 mo
Funding rounds
- Mar 2024Series A$150M
- Oct 2023Seed—
Founders & team
Investors
Catalio Capital Management, Third Rock Ventures, Novo Holdings, Vivo Capital, Cure Ventures, Pictet Group
Funding & investor landscape
$2.4Btotal disclosed funding
69companies funded
448disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Irving Weinberg
Co-Founder · Promaxo
Michael Bartholomew
Co-Founder · Promaxo
Jeff Galvin
Chief Executive Officer · American Gene
Richard Cliff
COO · Cellphire Therapeutics
Mike Gaffney
CEO · Cellphire Therapeutics
M Aman
Founder · Abvacc
Anthony Saleh
Co-Founder & CEO · miRecule
Michael Ruff
Founder & CEO · Creative Bio-Peptides
Moon Noh
CEO · TissueGene
Shibin Zhou
Co-Founder · Clasp Therapeutics
Kenneth Kinzler
Co-Founder · Clasp Therapeutics
Kevin Yim
Co-founder · Sigmovir
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
How many Life Sciences companies are there in Rockville, United States?
Radar tracks 117 indexable Life Sciences companies headquartered in Rockville, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Rockville, United States?
The Life Sciences companies in Rockville, United States on this list have raised a combined $2.4B in disclosed equity funding across 69 funded companies.
Which is the highest-funded Life Sciences company in Rockville, United States?
Sucampo is the highest-funded Life Sciences company in Rockville, United States, with $300M in disclosed equity funding.
How many Life Sciences companies in Rockville, United States are funded?
69 of the 117 Life Sciences companies in Rockville, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Rockville, United States?
None of the Life Sciences companies in Rockville, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Rockville, United States Life Sciences companies?
The most active investors in Rockville, United States Life Sciences companies on this list include HHS, Business Innovation Network, NIH, TEDCO, Emerging Technology Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.